Recent Progress and Prospects of Immunotherapy in Multidrug-Resistant and Metastatic Breast Cancer Treatment
Author:
Publisher
Springer International Publishing
Link
https://link.springer.com/content/pdf/10.1007/16833_2023_136
Reference105 articles.
1. Alavi AS, Acevedo L, Min W, Cheresh DA (2007) Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res 67(6):2766–2772
2. Al-Harras MF, Houssen ME, Shaker ME, Farag K, Farouk O, Monir R, El Mahdy R, Abo-Hashem EM (2016) Polymorphisms of glutathione S-transferase π 1 and toll-like receptors 2 and 9: association with breast cancer susceptibility. Oncol Lett 11(3):2182–2188
3. Amaral T, Meraz-Torres F, Garbe C (2017) Immunotherapy in managing metastatic melanoma: which treatment when? Expert Opin Biol Ther 17(12):1523–1538
4. Ansell SM, Vonderheide RH (2013) Cellular composition of the tumor microenvironment. Am Soc Clin Oncol Educ Book 33:e91
5. Ayoub NM, Al-Shami KM, Yaghan RJ (2019) Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer Targets Ther 11:53–69
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3